Outcome of right ventricular microaxial pump support in patients undergoing cardiac surgery.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Heart Failure* ; Cardiac Surgical Procedures*; Adult ; Humans ; Retrospective Studies ; Hospital Mortality ; Survival Rate ; Treatment Outcome
    • Abstract:
      Right ventricular failure (RVF) after cardiac surgery is associated with an in-hospital mortality rate of up to 75%. Microaxial flow pumps are one of the mechanical circulatory supports (MCS) options available for the treatment of RVF, however the specifics of timing and indication for MCS, as well as predictors for survival, remain unclear due to a dearth of published data. We evaluated the clinical outcome of patients treated with Impella-RP for predictors of mortality and the hemodynamic effects of the pump. This is a single-center retrospective observational study involving adult patients who underwent cardiac surgery with cardiopulmonary bypass between January 2019 and December 2020 in cardiac surgery and required therapeutic management of RVF with an Impella-RP. Overall, 18 patients were included and analyzed for factors that could be associated with mortality, or that could be predictors of patient outcomes for this population. Treatment of RVF with Impella-RP improved the patient hemodynamics significantly and had a survival rate of 61% within 30 days. Patients with isolated CABG or better liver function before implantation had a better survival rate, which may indicate that underlying disease and timing of implantation are significant for successful treatment of RVF.
      (© 2024. The Author(s).)
    • References:
      J Am Soc Echocardiogr. 2024 Feb 12;:. (PMID: 38354759)
      Am J Cardiol. 2017 Mar 15;119(6):845-851. (PMID: 28040188)
      Anesth Analg. 2009 Feb;108(2):422-33. (PMID: 19151265)
      J Thorac Cardiovasc Surg. 2018 Nov;156(5):1885-1891. (PMID: 29861112)
      Open Heart. 2020 Mar 4;7(1):e001214. (PMID: 32201591)
      Card Fail Rev. 2019 Nov 04;5(3):140-146. (PMID: 31768270)
      J Am Coll Cardiol. 2001 Jan;37(1):37-43. (PMID: 11153770)
      J Thorac Cardiovasc Surg. 2010 May;139(5):1316-24. (PMID: 20132950)
      J Heart Lung Transplant. 2015 Dec;34(12):1549-60. (PMID: 26681124)
      Int J Cardiol. 2020 Mar 1;302:135-137. (PMID: 31866154)
      Catheter Cardiovasc Interv. 2021 Jan 1;97(1):E161-E167. (PMID: 32569445)
      J Pers Med. 2022 Sep 09;12(9):. (PMID: 36143266)
      Cardiology. 2012;121(4):263-73. (PMID: 22626882)
      J Heart Lung Transplant. 2011 Dec;30(12):1360-7. (PMID: 21868253)
      J Heart Lung Transplant. 2018 Dec;37(12):1448-1458. (PMID: 30241890)
      Catheter Cardiovasc Interv. 2020 Aug;96(2):376-381. (PMID: 32129576)
    • Publication Date:
      Date Created: 20240405 Date Completed: 20240408 Latest Revision: 20240409
    • Publication Date:
      20240409
    • Accession Number:
      PMC10997586
    • Accession Number:
      10.1038/s41598-024-58602-w
    • Accession Number:
      38580761